DOI:
10.1055/s-00000146
Diabetes aktuell
LinksClose Window
References
Home PD et al.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabete (RECORD): a multicentre, randomised, open-label trial.
Lancet 2009;
373: 2125-2135
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.